US EditionPublished • loading... • Updated
Allergan Aesthetics Presents Data on Investigational Neurotoxin and GLP-1 Patient Trends
Summary by Plastic Surgery Practice
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Allergan Aesthetics Presents Data on Investigational Neurotoxin and GLP-1 Patient Trends
Phase 3 data show consistent safety with repeat TrenibotE treatments, while survey findings highlight growing aesthetic demand among patients using GLP-1 weight loss drugs. Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology (ADD) Meeting, including new data on an investigational neurotoxin and insights into patients using GLP-1 agonists for weight loss. “At Allergan Aesthetics, we are dedicated …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
